NCT01606280已完成不适用
Reporting of Amyloidosis Stem Cell Transplantation Outcomes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Survival
研究概览
简要总结
This study examines the value of stem cell transplantation in managing light chain amyloidisis.
详细描述
-
How does age at diagnosis affect prognosis in primary amyloidosis?
-
How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis?
-
How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis?
-
How does initial treatment affect prognosis in primary amyloidosis?
-
How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible for Stem cell transplantation less than age 75
排除标准
- •Creatinine > 3.0
- •BNP > 10000
结局指标
主要结局
Survival
时间窗: up to 8 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Mixed Chimeric Transplantation for Primary AmyloidosisAmyloidosisNCT00186095Stanford University
已完成
3 期
Intensive Versus Conventional Treatment in Patients With Primary AmyloidosisPrimary Systemic Amyloidosis (AL)NCT00344526University Hospital, Limoges100
已完成
2 期
Risk-adapted Therapy for Primary Systemic (AL) AmyloidosisAmyloidosisNCT01527032FDA Office of Orphan Products Development
已完成
2 期
Autologous Stem Cell Rescue for Primary AmyloidosisBlood and Marrow Transplant (BMT)AmyloidosisNCT00186407Stanford University50
已完成
2 期
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisMultiple Myeloma and Plasma Cell NeoplasmNCT00458822Memorial Sloan Kettering Cancer Center40